Cargando…

SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life

INTRODUCTION: For terminally-ill children with brain tumors care focuses on quality of life, and patient management fundamentally affects grieving families. We describe our experience of palliative sedation (PS) for children with refractory symptoms caused by solid tumors, focusing on BT (brain tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Podda, Marta, Schiavello, Elisabetta, Clerici, Carlo Alfredo, Biassoni, Veronica, Simonetti, Fabio, Massimino, Maura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165207/
http://dx.doi.org/10.1093/neuonc/noac079.674
_version_ 1784720336872275968
author Podda, Marta
Schiavello, Elisabetta
Clerici, Carlo Alfredo
Biassoni, Veronica
Simonetti, Fabio
Massimino, Maura
author_facet Podda, Marta
Schiavello, Elisabetta
Clerici, Carlo Alfredo
Biassoni, Veronica
Simonetti, Fabio
Massimino, Maura
author_sort Podda, Marta
collection PubMed
description INTRODUCTION: For terminally-ill children with brain tumors care focuses on quality of life, and patient management fundamentally affects grieving families. We describe our experience of palliative sedation (PS) for children with refractory symptoms caused by solid tumors, focusing on BT (brain tumor). METHODS: Retrospective data on all children treated for cancer who died between 1/2016-12/2020 in our Institution were collected. RESULTS: Of the 29 patients eligible for the study, M/F 17/12, the median duration of disease was 12.5 months(range 3-51) and the median age at death was 8.5 years(range 1-22). Fifteen had BT (5 DIPG, 2 Ependymoma, 8 high-grade-glioma). The reasons for starting PS in BT were: seizures(5), central respiratory failure(6), locked-in-syndrome(1), decerebration(1). Midazolam was combined in 16 cases with other drugs (neuroleptics, alpha-2 agonists, antihistamines) to achieve adequate sedation. Ten/15 with BT received antiepileptic therapy, apart midazolam. BT patients received oral benzodiazepins before PS less frequently than those with other cancers (p = 0.0033). Throughout the period of PS and on the day of death, patients with BT were given lower doses of midazolam and morphine. Mean dose of midazolam was 0.027 mg/kg/h (range 0.0069-0.06) for patients with BT, 0.055 mg/kg/h (range 0.01-0.38) for the others, while the mean morphine doses were 0.048 mg/kg/h (range 0-0.08) and 0.09 mg/kg/h (range 0.013-0.13), respectively. CONCLUSIONS: BT patients require less intensive analgesic-sedative therapies because their already impaired state of consciousness. Optimizing pharmacological treatments demands a medical team that knows how drugs (even developed for other indications) work. Emotional-relational aspects are important too, any action to lower a patient’s consciousness should be explained to the family. Guidelines on PS in pediatrics could help, providing they acknowledge that any child’s death is always a unique case.
format Online
Article
Text
id pubmed-9165207
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91652072022-06-05 SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life Podda, Marta Schiavello, Elisabetta Clerici, Carlo Alfredo Biassoni, Veronica Simonetti, Fabio Massimino, Maura Neuro Oncol Social Work/Patient Support/Palliative Care INTRODUCTION: For terminally-ill children with brain tumors care focuses on quality of life, and patient management fundamentally affects grieving families. We describe our experience of palliative sedation (PS) for children with refractory symptoms caused by solid tumors, focusing on BT (brain tumor). METHODS: Retrospective data on all children treated for cancer who died between 1/2016-12/2020 in our Institution were collected. RESULTS: Of the 29 patients eligible for the study, M/F 17/12, the median duration of disease was 12.5 months(range 3-51) and the median age at death was 8.5 years(range 1-22). Fifteen had BT (5 DIPG, 2 Ependymoma, 8 high-grade-glioma). The reasons for starting PS in BT were: seizures(5), central respiratory failure(6), locked-in-syndrome(1), decerebration(1). Midazolam was combined in 16 cases with other drugs (neuroleptics, alpha-2 agonists, antihistamines) to achieve adequate sedation. Ten/15 with BT received antiepileptic therapy, apart midazolam. BT patients received oral benzodiazepins before PS less frequently than those with other cancers (p = 0.0033). Throughout the period of PS and on the day of death, patients with BT were given lower doses of midazolam and morphine. Mean dose of midazolam was 0.027 mg/kg/h (range 0.0069-0.06) for patients with BT, 0.055 mg/kg/h (range 0.01-0.38) for the others, while the mean morphine doses were 0.048 mg/kg/h (range 0-0.08) and 0.09 mg/kg/h (range 0.013-0.13), respectively. CONCLUSIONS: BT patients require less intensive analgesic-sedative therapies because their already impaired state of consciousness. Optimizing pharmacological treatments demands a medical team that knows how drugs (even developed for other indications) work. Emotional-relational aspects are important too, any action to lower a patient’s consciousness should be explained to the family. Guidelines on PS in pediatrics could help, providing they acknowledge that any child’s death is always a unique case. Oxford University Press 2022-06-03 /pmc/articles/PMC9165207/ http://dx.doi.org/10.1093/neuonc/noac079.674 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Social Work/Patient Support/Palliative Care
Podda, Marta
Schiavello, Elisabetta
Clerici, Carlo Alfredo
Biassoni, Veronica
Simonetti, Fabio
Massimino, Maura
SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life
title SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life
title_full SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life
title_fullStr SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life
title_full_unstemmed SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life
title_short SWK-02. Palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life
title_sort swk-02. palliative sedation in pediatric patients suffering from brain tumors: choosing the best drugs to improve end of life
topic Social Work/Patient Support/Palliative Care
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165207/
http://dx.doi.org/10.1093/neuonc/noac079.674
work_keys_str_mv AT poddamarta swk02palliativesedationinpediatricpatientssufferingfrombraintumorschoosingthebestdrugstoimproveendoflife
AT schiavelloelisabetta swk02palliativesedationinpediatricpatientssufferingfrombraintumorschoosingthebestdrugstoimproveendoflife
AT clericicarloalfredo swk02palliativesedationinpediatricpatientssufferingfrombraintumorschoosingthebestdrugstoimproveendoflife
AT biassoniveronica swk02palliativesedationinpediatricpatientssufferingfrombraintumorschoosingthebestdrugstoimproveendoflife
AT simonettifabio swk02palliativesedationinpediatricpatientssufferingfrombraintumorschoosingthebestdrugstoimproveendoflife
AT massiminomaura swk02palliativesedationinpediatricpatientssufferingfrombraintumorschoosingthebestdrugstoimproveendoflife